Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Curr Hypertens Rep. 2012 Dec;14(6):603-7. doi: 10.1007/s11906-012-0302-7.
There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.
在过去的十年中，人们对儿童和青少年高血压治疗的理解发生了演变。这在一定程度上是由于越来越多的人关注这一临床问题，因为越来越多的儿童和青少年被诊断出患有这种疾病。此外，已经完成了越来越多的临床试验，这些试验证明了降压药的降压效果和这些药物的副作用特征，这导致了许多降压药被 FDA 批准用于儿童和青少年。然而，这些试验都没有提供关于这种患者人群的最佳一线药物的明确数据。本综述中讨论的临床经验和其他方法仍然是指导青少年高血压治疗所必需的。寻找最佳降压药才刚刚开始，要实现这一目标还需要付出非凡的努力。
